Acid Exfoliation Technology: Market Positioning Guide

Overview #

pH is not just a formulation parameter in acid exfoliation — it is your primary brand differentiator. Most brand owners come to us with a percentage on a brief. “5% glycolic.” “10% lactic.” What they haven’t thought through is what that number actually means to a consumer, what it means to a regulator, and what it means on a production line at 200kg scale. Those three things rarely align the way the brief assumes. Acid exfoliation is one of the most crowded categories in skincare, and the brands that win aren’t the ones with the highest acid concentration — they’re the ones who’ve built a defensible, coherent positioning story from ingredient selection through to on-pack language.

The Acid Landscape: Choosing Your Positioning Lane #

There are more acid options available today than most brand owners realize, and the choice isn’t just chemical — it’s a market positioning decision. AHAs, BHAs, PHAs, LHAs, and multi-acid blends each carry different consumer associations, different regulatory ceilings, and very different formulation constraints.

The EU ceiling for AHAs is the one that catches brands off guard most often. Under EU Cosmetics Regulation 1223/2009, leave-on AHA products above 10% or below pH 3.5 require a specific warning label. Drop below pH 3.5 and you’re in regulatory grey territory. Most brands don’t realize this until we tell them — usually after the brief is already locked.

PHAs are genuinely underutilized from a positioning standpoint. Gluconolactone and lactobionic acid deliver measurable exfoliation with a much gentler consumer experience, and they don’t carry the same regulatory burden. For brands targeting sensitive skin or the “gentle actives” positioning, this is often the smarter lane. We’ve been recommending this shift to several partners over the past two years, and the market response has been positive.

Salicylic acid sits in a different category entirely. At 2%, it’s a cosmetic in most markets. Above that, you’re looking at drug classification in the US under FDA Cosmetics Guidelines. That’s a conversation we have early in every acne-positioning brief.

What Clinical Language Is Actually Defensible #

This is where most brand owners get into trouble. There’s a significant gap between what sounds good in a marketing deck and what you can actually put on a label or in advertising copy without triggering a regulatory challenge.

Here’s the head-to-head data that’s actually useful. One double-blind, vehicle-controlled clinical study (n=40, 12 weeks) on a 10% glycolic acid formulation at pH 3.8 showed a 34% improvement in skin texture scores versus baseline, with a 28% reduction in fine line appearance as measured by profilometry. What that study doesn’t tell you — and what we’ve learned from our own batches — is that those results are highly packaging-dependent. The same formula in a jar versus an airless pump showed measurable potency differences by week 8 of stability testing.

Defensible claim language generally falls into three tiers:

Tier 1 — Structural/functional claims (lowest risk): “Exfoliates dead skin cells,” “smooths skin texture,” “unclogs pores.” These describe a physical process and are generally acceptable across EU, US, and NMPA frameworks under NMPA Cosmetic Regulation.

Tier 2 — Outcome claims with qualification: “Visibly smoother skin in 4 weeks” — acceptable if you have consumer perception data or a small IRB study to back it. We can help generate this data through our in-house efficacy testing partnerships.

Tier 3 — Quasi-drug territory (high risk): “Treats acne,” “reduces hyperpigmentation,” “reverses signs of aging.” These trigger drug classification in most markets. We push back hard when brands try to use this language for cosmetic-positioned products. It’s not worth the regulatory exposure.

Honestly, most brands underestimate how much the SCCS opinion shapes what’s defensible in Europe. The SCCS Scientific Opinion on AHA safety is the document your EU distributor will reference if your product gets flagged. We keep it on file for every AHA project we run.

Where Most Brands Get This Wrong #

Concentration is not the differentiator you think it is. We see this constantly — a brand comes in wanting “the highest glycolic acid serum on the market” as their positioning. The problem is that at 10% glycolic, pH 3.5, you’re already at the EU regulatory ceiling. You can’t go higher without triggering warning label requirements that will kill your premium positioning. And your competitor can match that concentration in about six months.

The real differentiator is the delivery system and the supporting cast. A 5% glycolic acid formula with a well-designed humectant base, a pH of 3.8, and a proper film-forming agent will outperform a 10% formula in a poorly buffered, high-water-activity base. We’ve seen this in our own stability and efficacy comparisons. The 10% number looks better on a spec sheet. The 5% formula performs better on skin.

This is usually where projects go sideways. The brand locks in a concentration claim before the formulation work starts, and then we’re reverse-engineering a formula to hit a marketing number rather than building a formula to hit a performance target. We almost always push back on this brief.

The other failure mode we see regularly: brands requesting a “multi-acid complex” with four or five acids at meaningful concentrations. Worked fine at 500g lab scale. At 200kg production, the pH drift during manufacturing became significant enough that we were hitting 3.2 at the end of the batch — below our target of 3.5 and outside EU compliance. We now require a tighter buffer system and mid-batch pH checks for any formula with more than two AHAs. It added about 15 minutes to the production cycle, but it solved the compliance problem.

For brands interested in how acid exfoliation intersects with barrier repair positioning, our barrier repair and sensitive skin formulation notes are worth reviewing before briefing. The combination of exfoliation and barrier support is one of the more interesting positioning spaces right now.

Capability Comparison: What to Actually Ask Your OEM #

Brand owners evaluating OEM partners for acid exfoliation products should be asking specific technical questions, not just requesting a capability list. Here’s what separates a factory that can make an acid product from one that can make a good acid product at scale.

pH control during manufacturing is the first thing we’d ask about. Acid formulas are sensitive to equipment material, mixing speed, and temperature during processing. Stainless steel tanks with the wrong surface finish can cause pH drift. We’ve seen it. Any competent acid formulation facility should be able to demonstrate batch-to-batch pH consistency within ±0.1 units.

Stability testing infrastructure matters more for acid products than almost any other category. AHAs are hygroscopic, and water activity changes during accelerated stability testing (40°C/75% RH, per ICH Stability Guidelines) can mask real-world performance issues. We run 6-month real-time alongside accelerated for every new acid formula — not because it’s required, but because the accelerated data alone has burned us before.

Packaging compatibility testing is non-negotiable. Acid formulas interact with packaging in ways that neutral-pH products don’t. We rejected the first packaging vendor on one recent project because their tube laminate showed measurable acid migration at week 4. The brand would never have caught that without in-house compatibility testing.

For brands also developing exfoliation-adjacent products like toners or essences, our toner and essence formulation resources cover the specific pH and preservative considerations for those formats.

The Cost Reality Nobody Talks About #

Acid exfoliation sounds like a simple category. It’s not. The raw material cost for pharmaceutical-grade glycolic acid versus cosmetic-grade is roughly 2.5× — and for a product where pH precision matters, grade selection is not optional. Most brands don’t budget for this difference.

Airless pump packaging for acid serums adds $0.40–$0.80 per unit at MOQ 3,000. Most indie brands can’t absorb that at launch, so they go with a dropper bottle. That’s a legitimate choice, but it has stability implications — dropper bottles have higher oxygen ingress, which matters for formulas with antioxidant co-actives. We’re not saying don’t use a dropper bottle. We’re saying know what you’re trading off.

Encapsulated acid systems — microencapsulated glycolic, for example — sound appealing for sensitive skin positioning. The release profile is more controlled, the consumer experience is gentler, and the marketing story is strong. The cost is roughly 3× the raw material cost of standard glycolic. We’re still not fully convinced the clinical evidence for encapsulated AHAs is strong enough to justify that premium for most brand tiers. The supplier data and our own stability results don’t always agree on release kinetics.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when an acid exfoliation brief comes in — because the answers determine almost everything else about the formulation approach.

A US-market glycolic serum targeting a professional skincare brand can sit at 10%, pH 3.5, with a straightforward AHA warning. That same formula cannot launch in the EU without the mandatory sun protection advisory on-pack. A Korean-market brightening toner with lactic acid needs to sit within NMPA-acceptable parameters if the brand has any intention of cross-registering for China. These aren’t afterthoughts — they’re formulation constraints that affect pH target, concentration ceiling, and preservative selection from day one.

For sensitive skin positioning, we typically recommend starting at 5% lactic or gluconolactone, pH 3.8–4.2, with a ceramide or panthenol co-active to support barrier function during the exfoliation cycle. For resurfacing or anti-aging positioning, glycolic at 8–10%, pH 3.5–3.8, with a niacinamide co-active for post-exfoliation brightening support. For acne-focused positioning, 1.5–2% salicylic acid in a low-comedogenic base, with careful preservative selection given the low pH environment.

Tell us your target market, your retail price point, and your on-pack claim ambition. We’ll tell you what’s achievable and what isn’t.

Frequently Asked Questions #

Q: We want to launch a “10% glycolic acid” serum in Europe — is that straightforward?

At 10%, you’re at the EU ceiling for leave-on AHAs. It’s doable, but you’ll need the mandatory sun protection warning on-pack, and your pH must stay at or above 3.5 throughout shelf life — not just at manufacture. We test pH at 0, 3, 6, and 12 months to confirm compliance holds.

Q: Can we combine glycolic and salicylic in the same formula?

Yes, but the pH window is tight. Salicylic acid performs best below pH 4.0; AHAs need to stay above pH 3.5 for EU compliance. That gives you a workable range of pH 3.5–4.0, but it’s narrow and requires careful buffering. Short answer: it’s possible, but we’d want to run stability before you commit to the combination on-pack.

Q: What’s the minimum order quantity for a custom acid formula?

Our standard MOQ for a custom acid serum is 1,000 units. Below that, the per-unit cost on pH-adjusted manufacturing and stability testing makes the economics difficult for both sides. For pilot batches, we can run 500 units with a development fee.

Q: We’ve seen “PHA” marketed as suitable for sensitive skin — is that actually true or just marketing?

It’s actually true, and it’s one of the more honest claims in this category. PHAs like gluconolactone have a larger molecular size than glycolic acid, which means slower skin penetration and a gentler exfoliation profile. In our internal consumer testing, irritation scores for 8% gluconolactone at pH 3.8 were consistently lower than 5% glycolic at the same pH. The trade-off is that the resurfacing effect is less dramatic — which is exactly what sensitive skin consumers want.

Q: How long does stability testing take before we can launch?

For a new acid formula, we require a minimum of 3 months accelerated stability (40°C/75% RH) plus 6 months real-time before we’d recommend a commercial launch. That’s roughly a 6–8 month timeline from formula lock to launch-ready stability data. Brands that try to compress this to 3 months accelerated only are taking a real risk — we’ve seen acid formulas pass accelerated and fail real-time, particularly in humid climates.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.